Letrozole Bristol Laboratories

Letrozole, the active ingredient in Letrozole Bristol Laboratories, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to treat postmenopausal estrogen receptor‑positive breast cancer, both in the adjuvant and metastatic settings.

GNH USA supplies Letrozole Bristol Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to EU GMP standards and provides regulatory‑approved batches to hospitals, pharmacies and procurement teams.

Letrozole is an aromatase inhibitor used in hormone‑responsive breast cancer management.

Postmenopausal estrogen receptor‑positive breast cancer: reduces recurrence risk and disease progression. Adjuvant treatment of hormone‑responsive breast cancer: improves disease‑free survival after surgery. Metastatic breast cancer: provides disease control when other endocrine therapies are unsuitable.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: intermittent pain. - Increased sweating.

Serious or Rare Side Effects: - Severe liver injury: elevated transaminases or hepatitis. - Bone fracture: decreased bone mineral density leading to fractures. - Deep vein thrombosis or pulmonary embolism. - QT interval prolongation on ECG. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Letrozole, clinicians should consider several safety precautions.

Pregnancy: contraindicated; teratogenic risk (Category X). Bone health: monitor bone mineral density; consider calcium/vitamin D supplementation. Liver function: assess hepatic enzymes before initiation and periodically. Cardiovascular risk: evaluate history of thromboembolic events. Drug interactions: review concomitant medications for CYP3A4 inducers or inhibitors. Store below 25°C: keep in original packaging, protect from moisture.

Letrozole may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Estrogen replacement therapy: antagonizes Letrozole’s aromatase inhibition. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce plasma concentrations. - Tamoxifen: opposing mechanisms may diminish therapeutic benefit. - Warfarin: increased anticoagulant effect, requiring INR monitoring. - Anticonvulsants that induce hepatic enzymes.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may raise Letrozole levels. - Selective serotonin reuptake inhibitors: potential additive hot‑flash effect. - Statins metabolised by CYP3A4: monitor for altered lipid‑lowering response.